Effect of brimonidine, measured with the Nerve Fibre Analyser, in patients with acute ischaemic optic neuropathy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON22790

Enrollment

Registered

2005-08-29

Start date

2001-02-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Topical treatment with Brimonidine (0.5%) eye drops.

Eligibility

Inclusion criteria

Inclusion criteria: Arteric or non-arteric AION.

Exclusion criteria

Exclusion criteria: 1. Onset of symptoms > 5 days ago at presentation; 2. Inability to undergo GDx or HFA measurement.

Design outcomes

Primary

Measure	Time frame
Thickness of peripapillary nerve fiber layer.	—

Contacts

Public ContactH.G. Lemij

Oogziekenhuis Rotterdam, Schiedamsevest 180

Lemij@oogziekenhuis.nl+31 (0)10 4017777

Outcome results